138642-96-3

Basic information

• Product Name: 6-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLIC ACID
• Synonyms: TIMTEC-BB SBB011255;6-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLIC ACID;ASISCHEM C71530;ASINEX-REAG BAS 07692362;BUTTPARK 13\05-83;Imidazo[1,2-a]pyridine-3-carboxylic acid, 6-chloro-2-methyl-;6-chloro-2-methylimidazo[1,2-a]pyridine-3-carboxylic acid(SALTDATA: FREE);3-Carboxy-6-chloro-2-methylimidazo[1,2-a]pyridine
• CAS NO: 138642-96-3
• Molecular Formula: C₉H₇ClN₂O₂
• Molecular Weight: 210.62
• Mol File: 138642-96-3.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLIC ACID(138642-96-3)
• EPA Substance Registry System: 6-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLIC ACID(138642-96-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 138642-96-3(Hazardous Substances Data)

Usage

General Description

6-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLIC ACID is a chemical compound with a molecular formula C8H5ClN4O2. It is a heterocyclic compound containing a chloro and a carboxylic acid functional group. 6-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLIC ACID has potential biological activity and is often used in pharmaceutical research as a precursor for the synthesis of new drugs. It may also be used as an intermediate in organic synthesis, particularly in the production of other heterocyclic compounds. Additionally, it has been studied for its potential antimicrobial and antifungal properties, making it a target for further investigation in the development of new medical treatments.

Upstream product

• 330858-13-4 ethyl 6-chloro-2-methylimidazo[1,2-a]pyridine-3-carboxylate 
• 1072-98-6 5-chloro-2-pyridylamine 

Downstream Products

• 1296202-56-6 7-chloro-N-(3-methoxybenzyl)-2-methylimidazo[1,2-a]pyridine-3-carboxamide 
• 1440650-53-2 7-chloro-N-(4-(4-fluorophenoxy)benzyl)-2-methylimidazo[1,2-a]pyridine-3-carboxamide 
• 1334716-80-1 N-([1,1'-biphenyl]-4-ylmethyl)-6-chloro-2-methylimidazo[1,2-a]pyridine-3-carboxamide 

Relevant articles and documents

Design, synthesis and biological evaluation of novel 1,2,3-triazole analogues of Imidazo-[1,2-a]-pyridine-3-carboxamide against Mycobacterium tuberculosis

Twenty-eight novel 1,2,3-triazole analogues of imidazo-[1,2-a]-pyridine-3-carboxamide were designed and synthesized based on hybridization approach. The structure of the final compounds are characterized using 1HNMR, 13CNMR, LCMS and

Design, synthesis, and biological evaluation of novel imidazo[1,2-a]pyridinecarboxamides as potent anti-tuberculosis agents

Tuberculosis (TB) is a highly infectious disease that has been plaguing the human race for centuries. The emergence of multidrug-resistant strains of TB has been detrimental to the fight against tuberculosis with very few safe therapeutic options availabl

Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug- resistant anti-tuberculosis agent

A critical unmet clinical need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy. In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compound 1, which led to the design and synthesis of Q203 (50). We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv. Linearity and lipophilicity of the amine part in the IPA series play a critical role in improving in vitro and in vivo efficacy and pharmacokinetic profile. The optimized IPAs 49 and 50 showed not only excellent oral bioavailability (80.2% and 90.7%, respectively) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) reduction (1.52 and 3.13 log10 reduction at 10 mg/kg dosing level, respectively) in mouse lung.